ISS X: Exploring the Science of Maintenance Therapy for Advanced Ovarian Cancer: Understanding Homologous Recombination Deficiency and Novel Targeted Strategies

MTCC: 701

This symposium is supported by AstraZeneca.

Faculty:
Michael Birrer, MD, PhD, University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute, Little Rock, AR

Description:
This program highlights the risk of recurrence in patients with advanced ovarian cancer and focuses on molecular pathways involved in tumorigenesis, including biomarkers of DNA-damage repair.

Top